n (%) | MACC1-AS1 | MACC1 | |||||
---|---|---|---|---|---|---|---|
Low and negative (n) | High (n) | P | Low and Negative (n) | High (n) | P | ||
Age (years) | 0.752 | 0.803 | |||||
≥55 | 72(58.5%) | 43 | 29 | 45 | 27 | ||
<55 | 51(41.5%) | 29 | 22 | 33 | 18 | ||
Sex | 0.351 | ||||||
Male | 76(61.8%) | 42 | 34 | 45 | 31 | 0.22 | |
Female | 47(38.2%) | 30 | 17 | 33 | 14 | ||
TNM stage | 0.022* | 0.002** | |||||
I | 17(13.8%) | 15 | 2 | 14 | 3 | ||
II | 25(20.3%) | 14 | 11 | 19 | 6 | ||
III | 43(35.0%) | 25 | 18 | 28 | 15 | ||
IV | 38(30.9%) | 18 | 20 | 17 | 21 | ||
Tumor invasion | 0.024* | 0.135 | |||||
T1 | 12(9.8%) | 10 | 2 | 9 | 3 | ||
T2 | 14(11.4%) | 10 | 4 | 11 | 3 | ||
T3 | 50(40.7%) | 29 | 21 | 31 | 19 | ||
T4 | 47(38.2%) | 23 | 24 | 27 | 20 | ||
Lymph node metastasis | 0.004** | 0.034* | |||||
N0 | 29(23.6%) | 22 | 7 | 13 | 13 | ||
N1 | 34(27.7%) | 20 | 14 | 20 | 14 | ||
N2 | 34(27.7%) | 22 | 12 | 23 | 11 | ||
N3 | 26(21.1%) | 8 | 18 | 22 | 7 | ||
Distant metastasis | 0.065 | 0.055 | |||||
M0 | 101(82.1%) | 63 | 38 | 68 | 33 | ||
M1 | 22(17.9%) | 9 | 13 | 10 | 12 | ||
Tumor differentiation | 0.963 | 0.923 | |||||
Well | 6(4.9%) | 5 | 1 | 5 | 1 | ||
Moderate | 20(16.3%) | 10 | 10 | 11 | 9 | ||
Poor | 97(78.9%) | 57 | 40 | 62 | 35 | ||
Mortality | 0.213 | 0.138 | |||||
Survive | 13(34.2%) | 8 | 5 | 8 | 5 | ||
die | 25(65.8%) | 10 | 15 | 9 | 16 | ||
Recurrence | 0.012* | 0.114 | |||||
No | 40(47.1%) | 31 | 9 | 32 | 8 | ||
Yes | 45(52.9%) | 23 | 22 | 29 | 16 |